Ardelyx, Inc. (ARDX) Reports Strong 2025 Revenue Growth, Updates 2026 Outlook

We recently published an article titled 10 Best Long Term Healthcare Stocks to Buy.

Ardelyx, Inc. (NASDAQ:ARDX) reported preliminary, unaudited product revenue results for the fourth quarter and full year 2025, along with expected product revenue for 2026 and an updated long-term outlook for Ibsrela. The company delivered strong commercial performance in 2025, with Ibsrela revenue increasing 73% year over year, while maintaining patient access to Xphozah. Ardelyx also advanced its development pipeline by initiating a Phase 3 program for Ibsrela in chronic idiopathic constipation and beginning work on a next-generation NHE3 inhibitor, RDX10531. Entering 2026, the company indicated it is positioned for continued growth, supported by expanding commercial opportunities, ongoing pipeline development, and a solid cash position. Ardelyx emphasized its focus on advancing first-in-class therapies addressing unmet medical needs while investing in commercialization and development efforts to support long-term value creation.

Recent developments include the initiation of a Phase 3 trial evaluating Ibsrela in chronic idiopathic constipation, a larger and underpenetrated indication that could expand the drug’s addressable market. Ardelyx, Inc. (NASDAQ:ARDX) continues to report strong year-over-year revenue growth for Ibsrela, alongside increasing Xphozah sales. Updated guidance reflects expectations for Ibsrela to exceed $1 billion in peak sales, supported by patent protection extending to 2041. Advancement of the next-generation NHE3 inhibitor RDX10531 adds an additional pipeline asset alongside ongoing commercialization efforts.

Ardelyx, Inc. (NASDAQ:ARDX) was founded in October 2007 and is headquartered in Waltham, Massachusetts. The company develops therapies targeting gastrointestinal, cardio-renal, and metabolic diseases.

While we acknowledge the potential of ARDX as a long term investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 8 Up and Coming Streaming Companies and Services and 9 High Growth Canadian Stocks to Buy

Disclosure: None.